Cardiac Sarcoidosis, Sarcoidosis, Cardiac, Sarcoidosis of the Heart, Sarcoidosis With Myocarditis
Conditions
Keywords
cardiac sarcoidosis, FDG-PET, disease activity, proteomics
Brief summary
The purpose of this study is to develop a prospective cohort of patients with and without cardiac sarcoidosis as well as active and inactive disease to develop a prospective biobank from which exosome analysis of peripheral blood will derive unique biomarkers of disease activity in cardiac sarcoidosis.
Interventions
OTHERExosome Analysis
Blood Samples will undergo exosome profiling using mass spectrometry and/or other discovery-based approaches
Sponsors
Mayo Clinic
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults ≥18 years. * Patients referred to the Cardiac Sarcoid Clinic with a clinical suspicion or a previously confirmed diagnosis of cardiac sarcoidosis. * Undergoing FDG-PET as part of standard care. * Ability to provide informed consent.
Exclusion criteria
• Inability to provide informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of successful biomarker validations | Baseline | Biomarker validation will be defined as ability to discriminate active from inactive or quiescent disease as assessed by FDG-PET |
Countries
United States
Contacts
CONTACTAnna Pick
PRINCIPAL_INVESTIGATORAndrew Rosenbaum, MD
Mayo Clinic
Outcome results
None listed